Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 605-610

  Arnedos, M ^a   Drury, S ^b   Afentakis, M ^c   A'Hern, R ^d   Hills, M ^c   Salter, J ^a   Smith, I E ^c,d   Reis Filho, J S ^e   Dowsett, M ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Immunohistochemistry; Relapse

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; STATHMIN;

ADULT; ARTICLE; CORRELATION ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; THERAPY RESISTANCE;

AROMATASE INHIBITOR; BREAST CANCER; IMMUNOHISTOCHEMISTRY; RELAPSE;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; STATHMIN; TAMOXIFEN; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84896867375     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt575     Document Type: Article

References (28)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348(24): 2431-2442.
2. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359(9324): 2131-2139.
3. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmeno-pausal women with early breast cancer. N Engl J Med 2005; 353(26): 2747-2757.
4. Martin LA, Ghazoui Z, Weigel MT et al. An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 2011; 76(8): 772-776.
5. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; 26(7): 1059-1065.
6. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrineresponsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26(34): 5569-5575.
7. Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 2005; 23(11): 2477-2492.
8. Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005; 11(2 Pt 2): 951s-958s.
9. Ellis MJ, Lin L, Crowder R et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010; 119(2): 379-390.
10. Ellis MJ, Miller WR, Tao Y et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 2009; 116(2): 371-378.
11. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30(6): 593-599.
12. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30(6): 587-592.
13. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21(11): 2101-2109.
14. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22): 3758-3767.
15. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22): 3748-3757.
16. Paridaens RJ, Dirix LY, Beex LV et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26(30): 4883-4890.
17. Anderson H, Hills M, Zabaglo L. et al. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol 2011; 22(8): 1770-1776.
18. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103 (5): 1742-1751.
19. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63(19): 6523-6531.
20. Massarweh S, Osborne CK, Creighton CJ et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68(3): 826-833.
21. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13(Suppl 1): S33-S43.
22. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5(1): 95-105.
23. Rocha RL, Hilsenbeck SG, Jackson JG et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997; 3(1): 103-109.
24. Lee AV, Jackson JG, Gooch JL et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999; 13(5): 787-796.
25. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104(18): 7564-7569.
26. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
27. Pinhel IF, Macneill FA, Hills MJ et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010; 12(5): R76.
28. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15(11): 1164-1168.